ESMO Breast 2022 | Optimizing adjuvant treatment in HR+/HER2- early breast cancer

Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, Korea, discusses optimizing adjuvant treatment in HR-positive, HER2-negative early breast cancer. Assessing patients’ Ki-67 score and genetic signature helps to guide optimal treatment and predict long-term outcomes of endocrine therapy to a more accurate degree than clinical and pathologic complete response (pCR). Dr Kim additionally notes on how neoadjuvant endocrine therapy is a good alternative to neoadjuvant chemotherapy for patients with HR-positive breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.